Described are medical devices including expandable tubular bodies configured to be implanted into a lumen, wherein the outer surface of the expandable tubular bodies are coupled to a polymer(s).

A coating agent can be applied to various materials without using radiation, and a medical material using the same. The coating agent containing a copolymer that contains: a monomer unit (unit A) containing a Si—O bond; a vinyl carboxylate monomer unit (unit B); and a monomer unit (unit C) containing a hydrophilic group.

The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

An example medical device includes a vascular device, such as a catheter, and an anti-thrombogenic coating on a surface of the vascular device, such as a surface likely to contact blood. The anti-thrombogenic coating includes one or more peptides configured to interact with fibrinogen in the blood, such as a first type of peptides configured to bind to fibrinogen a second type of peptides configured to inhibit conversion of fibrinogen to fibrin. The anti-thrombogenic coating also includes a polymer, such as a hydrocolloid polymer, a tunable polyethylene glycol (PEG), or other controlled release polymer configured to control release of the one or more peptides and maintain a concentration of the peptides at the surface of the anti-thrombogenic coating above a minimum inhibitory concentration, thereby inhibiting thrombin formation on the intravascular medical device.

A medical material uses a nickel-titanium alloy wherein a polyelectrolyte has a reduced thickness while a sufficient amount of an antithrombogenic compound for production of a therapeutic effect is supported. The medical material in which a porous surface is formed on a nickel-titanium alloy to allow infiltration of a polyelectrolyte into the pores, to thereby reduce the thickness of the polyelectrolyte exposed on the surface of the nickel-titanium alloy while allowing supporting of a sufficient amount of an antithrombogenic compound due to contribution of the polyelectrolyte infiltrate.

A venous access catheter shaft and method of using and manufacturing such a catheter is provided. In one aspect of the invention, a catheter is provided comprising a base polymer having a Shore A durometer of 85A or lower, with 2.0% percent by weight of surface modifier, and a radiopaque filler comprising between 20-40 percentage by weight. In another aspect of the invention, a method reducing thrombus accumulation on a venous access catheter is provided wherein the catheter surface's resistance to thrombus formation is enhanced during indwell time by lowering the durometer rating of the base polymer of the catheter without increasing the amount of surface modifier additive. In another aspect of the invention, a method of manufacturing a catheter shaft is provided, wherein the shaft is formed comprising a base polymer having a Shore A durometer of 85A or lower, with 2.0% percent by weight of surface modifier, and a radiopaque filler comprising 30% by weight barium sulfate, and optionally a colorant of 0.2% weight.

The present invention provides catheter compositions that provide anti-thrombogenic properties while not adversely impacting mechanical properties. All embodiments of the present invention comprise a catheter that comprises a fluoropolymer additive with specific compositions and/or purity levels.

The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.